| Open Document File Size: 705,55 KBShare Result on Facebook
City Pérez / Madrid / Francisco / Dominant / Groningen / Buxton / Valencia / Cancela / Soroka / Keith / Morton / Mittleman / Mannstadt / Gil / / Company 6Tolley Health Economics Ltd / ACE / Shire Pharmaceuticals Spain / Slobbe LC / Navis / Draibe SA / Spain LC / For SA / Pharmacoenomics & Outcomes Research Iberia / Jamal SA. / Creative Commons / / Country Netherlands / Japan / United States / United Kingdom / Spain / / Currency EUR / / / Facility Hospital Clínico San Carlos / Hospital Fundación Jiménez Díaz / / IndustryTerm healthcare payer perspectives / tunica media / healthcare / pharmaceutical / treatment of hyperphosphatemia / after failure / treatment of hyperphosphatemia in Chronic Kidney Disease / healthcare system perspective / healthcare context / / MedicalCondition vascular disease / Dialysis Background Chronic kidney disease / end stage kidney disease / chronic renal failure / hypercoagulability / small cell lung cancer / Chronic Kidney Disease / disorder / glomerulonephritis / renal disease / end-stage renal disease / MS / Utilities Disease / hypertension / disease / kidney disease / hyperphosphatemia / chronic / cardiovascular disease / diabetes / vomiting / lung cancer / hypercalcemia / Kidney Disease Outcomes Quality Initiative / male Renal disease / / MedicalTreatment hemodialysis / dialysis / / OperatingSystem Dos / / Organization Bank of England / National Health Service / Ministry of Health / / Person Van Baal / García Cortés / Lorenzo V / Van Exel / Norma Estatal / / Position MP / Robinson DM / WB / De Wit GA / General / WB / author / representative / / Product calcium acetate / Fosrenol / Ramipril / / ProvinceOrState New Jersey / Alabama / Maryland / South Dakota / Montana / Mississippi / Georgia / Massachusetts / Arkansas / / Technology Genomics / pdf / http / simulation / dialysis / / URL http /
SocialTag |
Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis